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Background: The Dutch Health Council recently recommended the introduction of a colo-
rectal cancer (CRC) screening programme by faecal occult blood testing (FOBT) for individ-
uals aged 55–75 at population risk of CRC. Individuals at an increased familial CRC risk (P2
times population risk) should be identified at a younger age, so they and their relatives can
receive earlier, more intensive surveillance instead of FOBT.
Aims: To determine the percentage of participants with a positive FOBT in a CRC screening
programme with an increased familial CRC risk.
Methods: In a population-based study, 10,569 individuals aged 50–75 received an FOBT.
Individuals with a positive FOBTwere invited for colonoscopy and familial risk assessment.
Participants with an average familial CRC risk were compared to those with an increased risk.
Increased familial CRC risk was defined as a cumulative lifetime risk of CRC of at least 10%.
Results: Of 6001 participants, 430 had a positive FOBT, of whom 324 (63% males; mean age
63 years) completed colonoscopy and familial risk assessment. CRC (n = 22) and/or advanced
adenomas (n = 122) were found in 133 participants. Familial CRC risk was increased in 6% of
participants with a positive FOBT. No significant differences were found between partici-
pants with an average versus an increased familial CRC risk.
Conclusion: Six percent of participants with a positive FOBT had an increased familial CRC
risk. Identifying at-risk participants enables them and their relatives to undergo regular
colonoscopies. Adding familial risk assessment to FOBT screening may thus prevent a sub-
stantial number of CRCs.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.t of Human Genetics 849, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500
4 361 3946; fax: +31 0 24 366 8774.
cn.nl (N. Hoogerbrugge).
article.
he Elsevier OA license.
1572 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 5 7 1 –1 5 7 71. Introduction mortality.11,12 It is considered cost-effective to recommend aIn Western society, the lifetime risk of developing colorectal
cancer (CRC) is 5–6%.1–3 In concordance with advice by the
European Union, the Health Council of The Netherlands rec-
ommended the introduction of a CRC screening programme
for individuals aged 55–75, consisting of a biennial faecal
occult blood test (FOBT), followed by colonoscopy in case of
a positive FOBT.4,5
Familial and hereditary CRCs account for 15–20% of all
CRCs.6–8 de Jong et al. found that 2.3% of the Dutch population
had multiple relatives with CRC and/or a relative with CRC
before the age of 50.7 Members of these families have an in-
creased familial CRC risk, i.e. a cumulative lifetime risk of
developing CRC of at least 10%. According to international
guidelines, these individuals should be identified at a younger
age than the advised screening age of 55–75 years, to receive
increased surveillance by regular colonoscopy.9,10 Surveillance
of moderate to high risk groups by regular colonoscopy
significantly reduces the incidence of CRC and CRC-relatedTable 1 – Variables measured in the study.
Variable
FOBT results
True positive CRC and/or advanced adenom
False positive All other or no pathology upon
Pathology results
Colorectal carcinoma Adenocarcinoma of the colore
Advanced adenoma Adenomas P10 mm, with high
Other lesions Any lesion except for colorecta
inflammations)
Personal history of
Any cancer Any malignant tumour
CRC Adenocarcinoma of the colore
Definite LSAT Epithelial ovarian carcinoma (i
malignancies of the endometr
tract and benign and malignan
Possible LSAT Abdominal tumours NOS, kidn
brain and urinary bladder
Family history
Family size The number of first-, second-,
Family history of CRC CRC in first-, second-, and/or t
Family history of LSAT LSAT in first-, second-, and/or
Family history of other cancers Other cancers than CRC or LSA
Familial CRC riska
Average (CRC risk <10%) Negative family history for CR
Moderate (CRC risk 10–15%) One relative with CRC < 50 yea
50 and 70 years
High (CRC risk >15%) Meeting Amsterdam I/II or Bet
Confounders
Possible signs of CRC Changed bowel habits, rectal b
bowel movement, unintention
Medication use Use of NSAIDS and/or anticoag
Smoking Smoking of any amount of tob
Alcohol use Drinking of any amount of alc
CRC = colorectal cancer; FOBT = faecal occult blood test; LSAT = Lynch
NSAIDs = non-steroidal anti-inflammatory drugs.
a Familial CRC risk = cumulative lifetime risk of developing CRC.
b Excluding bleeding from known haemorrhoids.colonoscopy every 6 years from the age of 45 years to individ-
uals with a moderate familial CRC risk of 10–15%.9,10,13,14 For
individuals with a high familial CRC risk above 15%, referral
to a clinical geneticist is recommended for more precise risk
assessment and determination of individualised preventive
measures.9,10,15
However, many individuals with an increased familial
CRC risk are still unidentified. If they are invited for popu-
lation CRC screening, three scenarios can occur: (1) they
decline to participate; (2) they have a negative FOBT; or (3)
they have a positive FOBT. With the current design of the
screening programme, only participants with a positive
FOBT are invited for colonoscopy and familial risk assess-
ment. Thus, individuals with an increased familial CRC risk
in the first two groups will remain unidentified as being
high-risk. As a consequence, they cannot benefit from
surveillance by regular colonoscopies; nor can their close





-grade dysplasia or a villous component P20%19
l carcinoma or advanced adenoma (e.g. benign polyps,
ctum
ncluding fallopian tube and primary peritoneal cancer), and
ium, stomach, biliary tract, small intestine, upper urinary
t tumours of the sebaceous glands9




T in first-, second-, and/or third-degree relatives
C and LSAT; or one relative with CRC > 50 years
rs, or two first- or second-degree relatives with CRC between
hesda criteria9,15,20,21





syndrome associated tumours; NOS = not otherwise specified; and
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participants in an FOBT screening programme.16,17 In both
studies, familial CRC risk was assessed using questionnaires,
which were sent along with the invitation for participation in
the screening programme. However, Navarro et al. excluded
individuals meeting criteria for Lynch syndrome, and only
determined whether participants had a positive family his-
tory, defined as having a family member with CRC, endome-
trial or kidney cancer.17 Worthley et al. found that 4.2% of
Australian participants had a familial CRC risk above 10%,
warranting increased surveillance.16 In the present study,
familial risk assessment was performed among participants
with a positive FOBT by an experienced nurse or gastroenter-
ologist to determine the percentage of – previously unidenti-
fied-participants in a Dutch CRC screening programme who
have an increased familial CRC risk.
2. Patients and methods
2.1. Study design and setting
From June 2006 to February 2007, a random sample of 10,569
individuals aged 50–75 in Nijmegen and surrounding areas
were invited to a pilot CRC screening programme. Individuals
were randomised to receive either a guaiac-based FOBT
(gFOBT) (Hemoccult II) or an immunochemical FOBT (iFOBT)Invited for the study 
n = 10,569 
FOBT completed 
n = 6,001 (57%) 
FOBT positive 
n = 430 (7%) 
Completed colonoscopy and 
familial risk assessment 
n = 324 (75%) 
Family history positive for CRC 
n= 55 (17%) 
Average familial CRC risk: n = 38 (12%) 
Increased familial CRC risk: n = 17 (6%) 
• Moderate (10-15%): n = 3 (0.9%) 
• High (> 15%): n = 14 (4%) 
Fig. 1 – Flow chart from invitation to familial risk assessment. A
developing colorectal cancer below 10%; CRC = colorectal cancer
cumulative lifetime risk of developing colorectal cancer of at lea(OC-sensor). This population-based study is described in de-
tail elsewhere.18
Individuals with a positive FOBT were invited for colonos-
copy. Everyone who accepted the invitation was seen by a spec-
ialised nurse or gastroenterologist who took a medical and
family history, with the aid of a checklist. If the family history
was positive for cancer, a more detailed pedigree was drawn.
Colonoscopy was performed by an experienced gastroen-
terologist. If possible, all observed neoplasms were removed,
and other lesions were biopsied, if necessary. Histology was
evaluated by an experienced pathologist. All colonoscopies
were completed in May 2007.
The study was reviewed and approved by the Dutch Health
Council. All participants gave written informed consent for
the FOBT and, if applicable, for colonoscopy.
2.2. Data collection
From the checklists filled in during the visit and medical re-
cords, the following items were collected: demographical data
(such as age and gender), FOBT results, pathology results, per-
sonal and family history of cancer and possible confounders.
Details and definitions are shown in Table 1. Familial CRC
risks were calculated from these data. Increased familial
CRC risk was defined as a cumulative lifetime risk of CRC of
at least 10%, i.e. a moderate or high familial CRC risk.9Declined FOBT 
n = 4,568 
FOBT negative 
n = 5,571 
Declined colonoscopy and/or 
familial risk assessment 
n = 106 
Family history negative for CRC 
n = 269 
verage familial CRC risk = cumulative lifetime risk of
; FOBT = faecal occult blood test; increased familial CRC risk:
st 10%.
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Descriptive statistics were used to characterise the study pop-
ulation, family history and familial CRC risk. Age compari-
sons between the groups with true and false positive FOBTs
were performed using independent samples T-tests (two-
tailed). Gender (male/female), test type (iFOBT/gFOBT), per-
sonal and family history of any cancer/CRC/Lynch syndrome
associated tumour (LSAT) (yes/no) and possible signs of
CRC, smoking and alcohol use (yes/no) were analysed as
dichotomous variables. These variables, as well as medication
use (none/non-steroidal anti-inflammatory drugs (NSAIDs)/
anticoagulants/combined use of NSAIDs and anticoagulants)
and familial CRC risk categories (not increased [average] and
increased [moderate or high]), were compared between par-
ticipants with true and false positive FOBTs, and between par-
ticipants with an average versus an increased familial CRC
risk, using Pearson Chi-Square tests.
Significance was defined at the p 6 0.05 level. All statistical
analyses were performed using SPSS version 16.0.
3. Results
3.1. Study population
Of the 10,569 participants, 57% (n = 6001) completed FOBT
(Hemoccult 51%, OC-Sensor 62%) (Fig. 1). A positive FOBT
was found in 430 participants (7%). The study population ofTable 2 – Baseline characteristics of 324 individuals with a posi
False positive F
N
Number of individuals (% of total) 191 59
Male gender 115 60
Mean age (SD) 62.1 (7.0)
Number of iFOBTs (versus gFOBTs)a 173 90
Colonoscopy resultsb
CRC 0 0
Advanced adenoma 0 0
Minor adenoma 67 20
Other pathology 59 30
No pathology 55 28
Possible signs of CRC
Changed bowel habits 9 4
Rectal blood lossc 19 10
Melena 1 0
Abdominal pain 14 7
Feeling of incomplete bowel movement 9 4





Alcohol use 153 80
CRC = colorectal cancer; FOBT = faecal occult blood test; gFOBT = guaiac
NSAIDs = non-steroidal anti-inflammatory drugs; and SD = standard dev
a p = 0.021.
b Results exceed 100%, since participants may have had more than one
c Excluding bleeding from known haemorrhoids.the present study consists of the 324 participants with a posi-
tive FOBT (75%) who completed colonoscopy and familial risk
assessment. The study population was predominantly male
(63%) with a mean age of 63 years (standard deviation
[SD] = 6.9) (Table 2).
CRC (n = 22) and/or advanced adenomas (n = 122) were
found in 133 participants. Thus, 41% of participants had a
true positive FOBT. The remaining 191 individuals had a false
positive FOBT, with minor adenomas (n = 77) and/or other
pathology (n = 81), or no pathology detected (n = 55).
No significant relevant differences were found between
participants with true versus false positive FOBTs.
3.2. Personal history of cancer
Details of personal and family history are shown in Table 3.
Approximately 10% of all participants reported a personal his-
tory of cancer (other than CRC and Lynch syndrome associ-
ated tumours). Three participants had a positive history of
CRC or LSAT.
3.3. Family history of colorectal cancer
Information on family size was reported in pedigrees of 38
participants (12%) and in most cases, only included the num-
ber of brothers, sisters and/or children. One participant was
adopted; no information on her biological relatives was
known. Fifty-five participants (17%) had a positive family his-tive FOBT in a CRC screening programme.
OBT True positive FOBT Total
% N % N %
.0 133 41.0 324 100
.2 90 77.7 205 63.3
63.4 (6.7) 62.6 (6.9)
.6 108 81.2 281 86.7
22 16.5 22 6.8
122 91.7 122 37.7
.7 10 30.9 77 23.8
.9 22 16.5 81 25.0
.8 0 0 55 17.0
.7 7 5.3 16 4.9
.0 24 18.0 43 13.3
.5 1 0.8 2 0.6
.3 8 6.0 22 6.8
.7 7 5.3 16 4.9
.2 4 3.0 12 3.7
.4 28 21.1 65 20.1
.7 2 1.5 9 2.8
.0 43 32.3 87 26.9
.1 102 76.7 255 78.7
-based FOBT; iFOBT = immunochemical FOBT; NA = not applicable;
iation.
type of pathology.
Table 3 – Personal and family history in 324 individuals with a positive FOBT in a CRC screening programme.
False positive FOBT (n = 191) True positive FOBT (n = 133)a Total (n = 324)
N % N % N %
Number of patients with personal history of
Any cancer 14 7.3 18 13.5 32 9.9
CRC/LSAT 1 0.5 2 1.5 3 0.9
Number of patients with FH of CRC
Positive FH of CRC 36 18.8 19 14.3 55 17.0
P1 FDR with CRC 36 18.8 19 14.3 55 17.0
P1 SDR with CRC 11 5.8 0 0 11 3.4
Unknowna 0 0 1 0.8 1 0.3
Number of patients with FH of definite/possible LSATb
Positive FH of LSAT 5 2.6 0 0 5 1.5
P1 FDR with LSAT 5 2.6 0 0 5 1.5
P1 SDR with LSAT 0 0 0 0 0 0
Unknowna 0 0 1 0.8 1 0.3
Number of patients with FH of other cancers
Positive FH of cancer 15 7.9 5 3.8 20 6.2
P1 FDR with cancer 15 7.9 5 3.8 20 6.2
P1 SDR with cancer 1 0.5 0 0 1 0.3
Unknowna 0 0 1 0.8 1 0.3
Familial CRC risk
Average 180 94.2 126 94.7 306 94.4
Moderate 2 1.0 1 0.8 3 0.9
High 9 4.7 5 3.8 14 4.3
Unknowna 0 0 1 0.8 1 0.3
CRC = colorectal cancer; FDR = first degree relative; FH = family history; FOBT = faecal occult blood test; LSAT = Lynch syndrome associated
tumours; definite LSAT = epithelial ovarian carcinoma (including fallopian tube and primary peritoneal cancer), and malignancies of the
endometrium, stomach, biliary tract, small intestine, upper urinary tract and benign and malignant tumours of the sebaceous glands; possible
LSAT = abdominal tumours not otherwise specified (NOS), kidney tumours NOS, pancreatic cancer, and carcinomas of the brain and urinary
bladder; and SDR = second degree relative.
a 1 Missing: family history unknown because of adoption.
b 3 Definite, 2 possible.
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positive FOBT.
3.4. Increased familial colorectal cancer risk
Six percent of participants had an increased familial CRC risk,
i.e. a familial CRC risk above 10% (n = 6 and n = 11 among par-
ticipants with true and false positive FOBTs, respectively).
Familial CRC risk was above 15% in 14 participants. In the
other 38 participants with a positive family history of CRC,
familial CRC risk was below 10%. No significant differences
were found between participants with an average versus an
increased familial CRC risk (data not shown).
4. Discussion
In this study, 17% of participants with a positive FOBT in a
CRC screening programme had a positive family history of
CRC. Six percent of participants had a familial CRC risk of at
least 10%. These prevalences are higher than previously re-
ported in the general Dutch population by de Jong et al.7 They
performed a study among 5072 Dutch individuals aged 45–70,
who filled in a questionnaire about the occurrence of CRC in
their first-degree relatives (FDRs). Eleven percent of the 3973
responders reported at least one FDR with CRC, while 2.3%of unaffected responders reported FDR with CRC diagnosed
before the age of 50, or two or more FDRs with CRC (i.e. a
familial CRC risk above 10%). We cannot exclude that a posi-
tive family history of CRC is one of the reasons to participate
in a screening programme.22 Also, advanced adenomas and
CRCs might occur more often in participants with an in-
creased familial CRC risk compared to those with a negative
family history.23,24 Since family history was not assessed in
participants with a negative FOBT and decliners, the number
of individuals with an increased familial CRC risk may there-
fore be higher in our study.
However, our results are in line with two other studies. First,
an Australian study, where 19.6% of 2538 participants in an
FOBT screening programme reported a positive family history
of CRC in a questionnaire.16 Of these participants, 106 (4.2%)
had a familial CRC risk high enough to warrant increased sur-
veillance by colonoscopy rather than participation in a screen-
ing programme. However, of the 377 participants with an
increased familial CRC risk, only 28 (7.4%) had a positive gFOBT
or iFOBT. In a Spanish study, 731 of 18,405 participants (4.9%) in
a gFOBT screening programme reported a positive family his-
tory, defined as having a family member with CRC, endometrial
or kidney cancer.17 Among those with a positive gFOBT, this
percentage was 11.0%; 7.3% of participants with a negative
gFOBT had a positive family history (p < 0.005).
1576 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 5 7 1 –1 5 7 7Strengths of our study include the assessment of family
history by a small number of nurses and gastroenterologists
who are very experienced in familial and hereditary CRC
and all determined familial CRC risk as defined by the most
recent guidelines.9 Moreover, the large number of participants
make for a good representation of the general population eli-
gible for FOBT screening.
A limitation of our study is that cancer diagnoses of rela-
tives were not verified in medical records. The accuracy of a
family history for CRC in first-degree relatives is very high,
approximately 90%.25,26 However, such accuracy is lower for
second- and third-degree relatives, and for other cancer
types, which can influence familial CRC risk. Since family his-
tory of colorectal cancer is correlated with family size, an-
other limitation of our study could be that information
about family size was mainly limited to first-degree relatives.7
In addition, a quarter of all individuals with a positive FOBT
did not complete colonoscopy and familial risk assessment,
leading to a possible selection bias. We cannot be sure that
no significant differences were present between individuals
who underwent a colonoscopy and those who did not. Partic-
ipants with a negative family history might feel that their risk
of developing CRC is lower than in those with a positive fam-
ily history and might, therefore, be less inclined to undergo
colonoscopy and familial risk assessment.22
We estimated the number of CRCs that may be prevented
by adding familial risk assessment to FOBT screening, based
on the following assumptions. The first assumption is that
the effectiveness of surveillance by regular colonoscopies in
individuals with an increased familial CRC risk is identical
to the effectiveness as described by Dove-Edwin et al. and
Jarvinen et al.11,12 In the study by Jarvinen et al., 6% of high-
risk participants undergoing surveillance developed CRC
during the 15-year follow-up of the trial, compared to 16%
of participants who did not undergo surveillance.12 Dove-
Edwin et al. showed that the incidence of CRC was 43% lower
in high-risk individuals, and 80% lower in participants with a
moderate familial CRC risk, than the expected incidence in
the absence of surveillance.11 The second assumption is that
participants have a mean number of three first-degree rela-
tives (i.e. brothers, sisters and children) whose CRC risk is
as high as that of the participant, and that these relatives
do not yet participate in the screening programme.13 Based
on these assumptions, an additional 172–184 CRCs may be
prevented annually among participants with a positive FOBT
and their relatives in the eligible Dutch screening population
of 3.5 million individuals (with an expected uptake of 60%).
This is just a tip of the iceberg, since many participants with
a negative FOBT, as well as non-participants, also have an
increased familial CRC risk.16,17
In conclusion, 6% of participants with a positive FOBT in a
CRC screening programme had a familial CRC risk above 10%.
Although the FOBT screening programme may serve as a way
to identify these individuals, they need referral for intensive
surveillance by regular colonoscopies instead of participating
in the FOBT screening programme. Adding familial risk
assessment to population screening with FOBT may, there-
fore, lead to the prevention of a substantial number of CRCs.
Other methods are needed to assess familial CRC risk among
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